Skip to Main Content
 

Global Search Box

 
 
 
 

Files

File List


osu1313426678.pdf (960.54 KB)

ETD Abstract Container

Abstract Header

Development of a Competitive Enzyme-Linked Immunosorbent Assay (ELISA) for Zeranol Detection and the Gene Regulation by Zeranol in Breast Cancer

Liu, Jie-Yu
http://rave.ohiolink.edu/etdc/view?acc_num=osu1313426678

Abstract Details

2011, Master of Science, Ohio State University, Veterinary Biosciences.
Zeranol, an anabolic growth promoter, has been widely used in the livestock industry. Due to its potent estrogenic activity, Zeranol is recognized as a potential carcinogenic agent for breast cancer. To further study the association between breast cancer and Zeranol consumption, we attempted to develop a direct competitive enzyme-linked immunosorbent assay (ELISA) for the detection and quantitation of Zeranol residues in the clinical samples from normal humans and breast cancer patients. Zearalanone, one of the major metabolites of Zeranol, was used as the hapten to produce the monoclonal antibody, anti-Zearalanone (anti-Z). The horseradish peroxidase-conjugated Zearalanone (HRP-Z) or HRP-conjugated Zeranol (HRP-z) was used to compete the limited binding sites of anti-Z with the Zeranol residues in samples. We have determined the optimal amount of anti-Z that can be placed on the plate, but pretty low signal was generated when HRP-Z was added to allow binding to anti-Z. The result suggests that anti-Z couldn’t recognize HRP-conjugated antigen for some reasons. In current study, the gene regulation of protein disulfide isomerase family A, member 3 (PDIA3) and estrogen receptor alpha (ESR1) by Zeranol has been investigated. Both in vitro and in vivo studies have shown that PDIA3 mRNA level was up-regulated but ESR1 was down-regulated in response to Zeranol. In the large-scale examination of human breast specimens, the same expression pattern was identified in primary cultured human breast cancer epithelial cells. ESR1 expression was negatively associated with the age; however, neither PDIA3 nor ESR1 was correlated with the pathological characteristics. The negative correlation between PDIA3 and ESR1 expression was found in cancer patients and certain pathological characteristics including high graded stage, non triple-negative breast cancer, peritumor lymphovascular invasion, estrogen receptor alpha positive, human epidermal growth factor receptor 2 negative, progesterone receptor positive, and T2 stage.
Young C. Lin (Committee Chair)
McDonald Wick (Committee Member)
Robert Lee (Committee Member)

Recommended Citations

Citations

  • Liu, J.-Y. (2011). Development of a Competitive Enzyme-Linked Immunosorbent Assay (ELISA) for Zeranol Detection and the Gene Regulation by Zeranol in Breast Cancer [Master's thesis, Ohio State University]. OhioLINK Electronic Theses and Dissertations Center. http://rave.ohiolink.edu/etdc/view?acc_num=osu1313426678

    APA Style (7th edition)

  • Liu, Jie-Yu. Development of a Competitive Enzyme-Linked Immunosorbent Assay (ELISA) for Zeranol Detection and the Gene Regulation by Zeranol in Breast Cancer. 2011. Ohio State University, Master's thesis. OhioLINK Electronic Theses and Dissertations Center, http://rave.ohiolink.edu/etdc/view?acc_num=osu1313426678.

    MLA Style (8th edition)

  • Liu, Jie-Yu. "Development of a Competitive Enzyme-Linked Immunosorbent Assay (ELISA) for Zeranol Detection and the Gene Regulation by Zeranol in Breast Cancer." Master's thesis, Ohio State University, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=osu1313426678

    Chicago Manual of Style (17th edition)

osu1313426678
530
© 2011, all rights reserved.
This open access ETD is published by The Ohio State University and OhioLINK.